HCV is a carcinogen that is well established as a major risk factor for hepatocellular carcinoma. Evidence that HCV plays a role in the development of extrahepatic malignancies is less robust; however, epidemiological studies have consistently demonstrated an association between HCV infection and B-cell non-Hodgkin lymphoma (NHL). The strongest evidence for a link between HCV and tumouri-genesis is the clear association between viral eradication, as indicated by achievement of sustained virological response, and remission of B-cell NHL. All-oral direct-acting antiviral-based therapies are effective in patients with HCV-associated NHL and well tolerated. For this reason, it is important that clinicians assess HCV-infected patients for HCV-associated extrahepatic malignancies so patients can receive timely diagnosis and treatment.
References
1.
TorresH.A., ShigleT.L., HammoudiN.The oncologic burden of hepatitis C virus infection: a clinical perspective.CA Cancer J Clin2017; 67: 411–431.
2.
Makarova-RusherO.V., AltekruseS.F., McNeelT.S.Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.Cancer2016; 122: 1757–1765.
3.
de Oliveria AndradeL.J., D'OliveiraA., MeloR.C., De SouzaE.C., Costa SilvaC.A., ParanaR.Association between hepatitis C and hepatocellular carcinoma.J Glob Infect Dis2009; 1: 33–37.
4.
FerriC., La CivitaL., CaraccioloF., ZignegoA.L.Non-Hodgkin's lymphoma: possible role of hepatitis C virus.JAMA1994; 272: 355–356.
5.
FerriC., CaraccioloF., ZignegoA.L.Hepatitis C virus infection in patients with non-Hodgkin's lymphoma.Br J Haematol1994; 88: 392–394.
6.
FerriC., MontiM., La CivitaL.Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia.Eur J Clin Invest1994; 24: 781–784.
7.
PozzatoG., MazzaroC., CrovattoM.Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia.Blood1994; 84: 3047–3053.
8.
SilvestriF., BarillariG., FaninR.Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin's lymphomas.Haematologica1997; 82: 314–317.
9.
ZuckermanE., ZuckermanT., LevineA.M.Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma.Ann Intern Med1997; 127: 423–428.
10.
HausfaterP., CacoubP., SterkersY.Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France.Am J Hematol2001; 67: 168–171.
11.
El-SeragH.B., HampelH., YehC., RabeneckL.Extrahepatic manifestations of hepatitis C among United States male veterans.Hepatology2002; 36: 1439–1445.
12.
de SanjoseS., NietersA., GoedertJ.J.Role of hepatitis C virus infection in malignant lymphoma in Spain.Int J Cancer2004; 111: 81–85.
13.
NietersA., KallinowskiB., BrennanP.Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH.Gastroenterology2006; 131: 1879–1886.
14.
GiordanoT.P., HendersonL., LandgrenO.Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.JAMA2007; 297: 2010–2017.
15.
SpinelliJ.J., LaiA.S., KrajdenM.Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada.Int J Cancer2008; 122: 630–633.
16.
OmlandL.H., FarkasD.K., JepsenP., ObelN., PedersenL.Hepatitis C virus infection and risk of cancer: a population-based cohort study.Clin Epidemiol2010; 2: 179–186.
17.
AllisonR.D., TongX., MoormanA.C.Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010.J Hepatol2015; 63: 822–828.
18.
RasulI., ShepherdF.A., Kamel-ReidS., KrajdenM., PantalonyD., HeathcoteE.J.Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia.Hepatology1999; 29: 543–547.
19.
GisbertJ.P., Garcia-BueyL., PajaresJ.M., Moreno-OteroR.Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis.Gastroenterology2003; 125: 1723–1732.
20.
MatsuoK., KusanoA., SugumarA., NakamuraS., TajimaK., MuellerN.E.Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies.Cancer Sci2004; 95: 745–752.
21.
NegriE., LittleD., BoiocchiM., La VecchiaC., FranceschiS.B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review.Int J Cancer2004; 111: 1–8.
22.
Dal MasoL., FranceschiS.Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies.Cancer Epidemiol Biomarkers Prev2006; 15: 2078–2085.
23.
de SanjoseS., BenaventeY., VajdicC.M.Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.Clin Gastroenterol Hepatol2008; 6: 451–458.
24.
MontiG., PioltelliP., SaccardoF.Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias.Arch Intern Med2005; 165: 101–105.
25.
TorresH.A., MahaleP.Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization.Liver Int2015; 35: 1661–1664.
26.
FerriC., SebastianiM., GiuggioliD.Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer.World J Hepatol2015; 7: 327–343.
27.
VallatL., BenhamouY., GutierrezM.Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection.Arthritis Rheum2004; 50: 3668–3678.
28.
HosryJ., MirandaR.N., SamaniegoF., EconomidesM.P., TorresH.A.Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.Int J Cancer2018; 142: 940–948.
29.
FerriC., Ramos-CasalsM., ZignegoA.L.International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement.Autoimmun Rev2016; 15: 1145–1160.
30.
SwerdlowS.H., CampoE., HarrisN.L.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.Lyon: IARC; 2008.
31.
FaziC., DagklisA., CottiniF.Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals.Cytometry B Clin Cytom2010; 78Suppl 2: S61–S68.
32.
MollejoM., MenarguezJ., Guisado-VascoP.Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study.Mod Pathol2014; 27: 281–293.
33.
MatutesE., OscierD., MontalbanC.Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.Leukemia2008; 22: 487–495.
34.
De VitaS., SaccoC., SansonnoD.Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection.Blood1997; 90: 776–782.
35.
ChesonB.D., FisherR.I., BarringtonS.F.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.J Clin Oncol2014; 32: 3059–3068.
36.
DreylingM., ThieblemontC., GallaminiA.ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.Ann Oncol2013; 24: 857–877.
37.
ArcainiL., LazzarinoM., ColomboN.Splenic marginal zone lymphoma: a prognostic model for clinical use.Blood2006; 107: 4643–4649.
38.
ChuangS.S., LiaoY.L., ChangS.T.Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas.J Clin Pathol2010; 63: 595–598.
39.
ThieblemontC., FelmanP., BergerF.Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.Clin Lymphoma2002; 3: 41–47.
40.
MahaleP., TorresH.A., KramerJ.R.Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study.Cancer2017; 123: 1202–1211.
41.
AntonelliA., FerriC., FallahiP.Thyroid cancer in patients with hepatitis C infection.JAMA1999; 281: 1588.
42.
AntonelliA., FerriC., FallahiP.Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study.Thyroid2007; 17: 447–451.
43.
ZignegoA.L., GianniniC., GragnaniL.HCV and lymphoproliferation.Clin Dev Immunol2012; 2012: 980942.
44.
JacobsonI.M., CacoubP., Dal MasoL., HarrisonS.A., YounossiZ.M.Manifestations of chronic hepatitis C virus infection beyond the liver.Clin Gastroenterol Hepatol2010; 8: 1017–1029.
45.
LandauD.A., RosenzwajgM., SaadounD., KlatzmannD., CacoubP.The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.Ann Rheum Dis2009; 68: 337–344.
SassoE.H., MartinezM., YarfitzS.L.Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t(14;18).J Immunol2004; 173: 3549–3556.
48.
ViscoC., WangJ., TisiM.C.Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.Br J Cancer2017; 117: 1685–1688.
49.
CanioniD., MichotJ.M., RabiegaP.In situ hepatitis C NS3 protein detection is associated with high grade features in hepatitis C-associated B-cell non-Hodgkin lymphomas.PLoS One2016; 11: e0156384.
50.
TerrierB., ChaaraW., DufatL.Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection.Autoimmun Rev2014; 13: 319–326.
51.
FiorinoS., Bacchi-ReggianiL., de BiaseD.Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: a systematic review.World J Gastroenterol2015; 21: 12896–12953.
52.
VannataB., ArcainiL., ZuccaE.Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?Ther Adv Hematol2016; 7: 94–107.
53.
ZignegoA.L., MacchiaD., MontiM.Infection of peripheral mononuclear blood cells by hepatitis C virus.J Hepatol1992; 15: 382–386.
54.
FerriC., MontiM., La CivitaL.Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia.Blood1993; 82: 3701–3704.
55.
SansonnoD., LotesoriereC., CornacchiuloV.Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers.Blood1998; 92: 3328–3337.
56.
ArrietaJ.J., Rodriguez-InigoE., CasqueiroM.Detection of hepatitis C virus replication by in situ hybridization in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus.Hepatology2000; 32: 97–103.
57.
CrovattoM., PozzatoG., ZoratF.Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus.Haematologica2000; 85: 356–361.
58.
De VitaS., De ReV., SansonnoD.Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis.Hepatology2000; 31: 182–189.
59.
NagaoY., SataM., NoguchiS.Detection of hepatitis C virus RNA in oral lichen planus and oral cancer tissues.J Oral Pathol Med2000; 29: 259–266.
60.
YanF.M., ChenA.S., HaoF.Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C.World J Gastroenterol2000; 6: 805–811.
61.
CarrozzoM., QuadriR., LatorreP.Molecular evidence that the hepatitis C virus replicates in the oral mucosa.J Hepatol2002; 37: 364–369.
62.
KurokawaM., HidakaT., SasakiH., NishikataI., MorishitaK., SetoyamaM.Analysis of hepatitis C virus (HCV) RNA in the lesions of lichen planus in patients with chronic hepatitis C: detection of anti-genomic- as well as genomic-strand HCV RNAs in lichen planus lesions.J Dermatol Sci2003; 32: 65–70.
63.
SansonnoD., LaulettaG., MontroneM., GrandalianoG., SchenaF.P., DammaccoF.Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection.Clin Exp Immunol2005; 140: 498–506.
64.
ZignegoA.L., Ramos-CasalsM., FerriC.International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement.Autoimmun Rev2017; 16: 523–541.
65.
HermineO., LefrereF., BronowickiJ.P.Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.N Engl J Med2002; 347: 89–94.
66.
MahaleP., EngelsE.A., LiR.The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.Gut2018; 67: 553–561.
67.
NahonP., BourcierV., LayeseR.Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications.Gastroenterology2017; 152: 142–156.e2.
68.
SaadounD., PolS., FerfarY.Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis.Gastroenterology2017; 153: 49–52.e5.
69.
WotherspoonA.C., DoglioniC., DissT.C.Regression of primary low-grade B-cell gastric lymphoma of mucosaassociated lymphoid tissue type after eradication of Helicobacter pylori.Lancet1993; 342: 575–577.
70.
StathisA., ChiniC., BertoniF.Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type.Ann Oncol2009; 20: 1086–1093.
71.
ZuckermanE., ZuckermanT., SaharD.The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection.Blood2001; 97: 1555–1559.
72.
Peveling-OberhagJ., ArcainiL., BankovK., ZeuzemS., HerrmannE.The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.J Viral Hepat2016; 23: 536–544.
73.
ArcainiL., VallisaD., RattottiS.Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.Ann Oncol2014; 25: 1404–1410.
74.
MichotJ.M., CanioniD., DrissH.Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.Am J Hematol2015; 90: 197–203.
75.
AlricL., BessonC., LapidusN.Antiviral treatment of HCV-infected patients with B-cell non-Hodgkin lymphoma: ANRS HC-13 Lympho-C Study.PLoS One2016; 11: e0162965.
76.
La MuraV., De RenzoA., PernaF.Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.J Hepatol2008; 49: 557–563.
77.
AASLD and IDSA.HCV Guidance: recommendations for testing, managing, and treating hepatitis C.2017. (Accessed November 2017.) Available from http://www.hcvguidelines.org/.
78.
ArcainiL., BessonC., FrigeniM.Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.Blood2016; 128: 2527–2532.
79.
PersicoM., AglittiA., CarusoR.Efficacy and safety of new direct antiviral agents in HCV infected patients with diffuse large B Cell non-Hodgkin lymphoma.Hepatology2018; 67: 48–55.
80.
BrancaccioG., SorboM.C., FrigeriF.Treatment of acute hepatitis C with ledipasvir and sofosbuvir in patients with hematological malignancies allows early re-start of chemotherapy.Clin Gastroenterol Hepatol2018; 16: 977–978.
81.
KawamuraY., IkedaK., AraseY.Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.Am J Med2007; 120: 1034–1041.
82.
DreylingM., CampoE., HermineO.Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2017; 28: iv62–iv71.
83.
European Association for the Study of the Liver (EASL).EASL recommendations on treatment of Hepatitis C 2016.J Hepatol2017; 66: 153–194.
84.
Ramos-CasalsM., ZignegoA.L., FerriC.Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.J Hepatol2017; 66: 1282–1299.
